Search results
Results From The WOW.Com Content Network
Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China ...
Sinopharm Group. Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In July 2020, Sinopharm began trials with 31,000 volunteers in the UAE in collaboration with G42 Healthcare, an Abu Dhabi-based company. [62] In June 2021, Sinopharm began Phase III trials for children and adolescents aged 3–17 with 1,800 volunteers. [63] In September 2020, Sinopharm began trials in Casablanca and Rabat on 600 people.
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [ 2 ][ 3 ] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
CoronaVac, also known as the Sinovac COVID-19 vaccine, [4] was a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. [5][6] It was phase III clinically trialled in Brazil, [7] Chile, [8] Indonesia, [9] the Philippines, [10] and Turkey [11] and relies on traditional technology similar to other inactivated ...
This page was last edited on 16 September 2021, at 05:01 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply.